
Opinion|Videos|February 5, 2025
Additional Considerations With PBC Therapies
Panelists discuss how recent FDA regulatory actions regarding obeticholic acid have raised concerns about its long-term safety profile and accessibility, leading health care teams to develop strategies for supporting patients through treatment transitions while navigating insurance coverage and access challenges for newer primary biliary cholangitis (PBC) therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How have recent FDA actions regarding obeticholic acid influenced perceptions of its long-term use in PBC treatment, and what broader implications might these regulatory actions have for patients and providers?
- How can health care teams support patients in navigating potential access or coverage challenges that may arise due to regulatory changes affecting PBC therapies, especially when considering a switch to newer treatments?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
5

















































































































